bladder cancer

News

ImmunityBio rises as route opens to broader Anktiva label

Shares in ImmunityBio shot up after it agreed a path with the FDA that should allow it to refile for wider use of its bladder cancer drug Anktiva.

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

EMA starts review of 'transformative' bladder cancer therapy

The EMA has started a review of a regimen based on Pfizer/Astellas' Padcev and MSD's Keytruda that is described as a game-changer for bladder cancer.

Oncology

Interview at ESMO 2025 with Sandeep Reddy, Immunity Bio

ESMO25: Harnessing the innate and the adaptive immune respon...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.

News

enGene's president and chief executive, Ron Cooper

Trial sets up filing for enGene bladder cancer gene therapy

enGene is hoping to file its gene for a form of bladder cancer before the end of 2026, based on phase 2 data revealing a 62% complete response rate.

News

J&J claims FDA okay for bladder cancer drug TAR-200

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.

ImmunityBio rises as route opens to broader Anktiva label

Padcev/Keytruda scores again in early bladder cancer

EMA starts review of 'transformative' bladder cancer therapy

ESMO25: Harnessing the innate and the adaptive immune respon...

Trial sets up filing for enGene bladder cancer gene therapy

J&J claims FDA okay for bladder cancer drug TAR-200

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

bladder cancer

Editor's Picks